Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of post-marketing surveillance data. Issue 3 (4th May 2021)

• Record Type: Journal Article
• Authors: Shimizu, Hirohito; Kobayashi, Hisanori; Kanbori, Masayoshi; Ishii, Yutaka
• Is Part Of: Modern rheumatology. Volume 31:Issue 3(2021)
• Page Start: 566
• Page End: 574
• Publication Date: 2021-05-04
• Subjects: Disease-modifying antirheumatic drugs -- golimumab -- post-marketing surveillance -- rheumatoid arthritis -- switching; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2020.1797283
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives: To assess the real-world effectiveness of golimumab in Japanese patients with rheumatoid arthritis who had previously received one or more biologic therapies. Methods: A post-hoc analysis of post-marketing surveillance was performed. The clinical response to golimumab was analyzed in 1216 patients who had previously received one or more biologic agents including non-TNF inhibitors with stratification by the number of previous biologic agents. Logistic regression analyses were conducted to identify factors associated with DAS28-CRP response to golimumab. Results: While treatment persistence is comparable, the response to golimumab declined with an increasing number of previous biologic therapies. When stratified by golimumab dose, patients receiving golimumab at 100 mg had higher disease activity at baseline with an increasing number of previous bDMARDs, but they still achieved comparable disease activity at 24 weeks regardless of how many bDMARDs had been previously used. Univariate and multivariate analyses both identified concomitant oral corticosteroid therapy as a factor negatively associated with the likelihood of achieving a DAS28-CRP response. Conclusion: Switching to golimumab was effective regardless of how many biologic agents had been previously used, but the response declined with an increasing number of prior biologic agents. A golimumab dose of 100 mg was also effective for those who previously received three or more bDMARDs.